Nash Clinical Trial - Study to Evaluate the Efficacy & Safety of K-877-ER

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05479721` - LITMUS Imaging Study
Recruiting	`NCT06308757` - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis	N/A
Completed	`NCT02923154` - Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)	Phase 2
Withdrawn	`NCT03980912` - Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
Terminated	`NCT04565717` - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 1
Not yet recruiting	`NCT05935488` - Early Liver Disease Breath Detection
Recruiting	`NCT04302051` - Assessment of Fatty Liver With Thermo-acoustic Device
Completed	`NCT06348706` - Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes	Phase 3
Active, not recruiting	`NCT06315361` - DIAbetes and NAFLD
Completed	`NCT03187496` - Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.	Phase 1
Not yet recruiting	`NCT06364462` - Precise Evaluation Criteria for Histological Regression of NASH Fibrosis
Recruiting	`NCT04442334` - The European NAFLD Registry
Recruiting	`NCT06338969` - The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis	N/A
Recruiting	`NCT05193916` - A Phase II Clinical Trial of Chiglitazar for NASH	Phase 2
Active, not recruiting	`NCT05669677` - Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Not yet recruiting	`NCT04783116` - Plant Stanols and Liver Inflammation in Overweight and Obese Children	N/A
Recruiting	`NCT06193629` - A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar	N/A
Completed	`NCT04006145` - A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH	Phase 2
Recruiting	`NCT04232293` - Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus	N/A
Not yet recruiting	`NCT04925362` - THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)	N/A

NCT number	NCT05327127
Study type	Interventional
Source	Kowa Research Institute, Inc.
Contact	Director, Clinical Operations
Phone	919-433-1600
Email	Clinical@KowaUS.com
Status	Recruiting
Phase	Phase 2
Start date	November 14, 2022
Completion date	June 2025

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms